Gene-Edited immune cells take aim at Virus-Linked cancer
NCT ID NCT00368082
Summary
This study is testing a new cell therapy for lymphoma that has come back after treatment and is linked to Epstein-Barr virus (EBV). Researchers are giving patients special immune cells (T cells) that have been genetically modified to resist a substance released by the tumor and trained to attack EBV-infected cancer cells. The main goals are to find a safe dose and see if this approach can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Childrens Hospital
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.